Notícias de Sichuan Kelun-Biotech Biopharmaceutical

Últimas notícias

Manchetes no idioma original da fonte.

• 
  Multiple Sacituzumab Tirumotecan (sac-TMT) Studies Selected as LBAs at ESMO 2026, OptiTROP-Lung04 and OptiTROP-Lung06 to be Presented in the Lung Cancer Session (abre em uma nova aba)

  22 de set. de 2026

• 
  Results from Phase III Study of Trastuzumab Botidotin versus T-DM1 in HER2-Positive Breast Cancer Published in JCO (abre em uma nova aba)

  14 de set. de 2026

• 
  Kelun-Biotech's Partner Windward Bio Announces Positive Phase 2 Results of SKB378/WIN378 in Asthma, and Initiates Phase 3 Study (abre em uma nova aba)

  8 de set. de 2026

• Why Merck Stock Got Downgraded After a Massive Cancer-Vaccine Win (abre em uma nova aba)

  20 de ago. de 2026

• Kelun-Biotech Announces 2026 Interim Results (abre em uma nova aba)

  17 de ago. de 2026

• Sichuan Kelun Biotech Biopharmaceutical (SEHK:6990) Following New TNBC Filing Has Valuation Back In Focus (abre em uma nova aba)

  2 de ago. de 2026

• Sichuan Kelun Biotech Biopharmaceutical (SEHK:6990) Stock May Trade At A Premium Despite Priority Review News (abre em uma nova aba)

  2 de ago. de 2026

• NMPA Accepts New Indication Application for Sacituzumab Tirumotecan (sac-TMT) as First-Line Treatment for Advanced TNBC (abre em uma nova aba)

  30 de jul. de 2026

• Kelun-Biotech Receives a Clinical Trial Notice for Its First Dual-payload ADC SKB565 (abre em uma nova aba)

  27 de jul. de 2026

• Harbour BioMed and Kelun-Biotech receive China IND approval for asthma therapy (abre em uma nova aba)

  16 de jul. de 2026

• Can Dow Jones' Merck Nab $25 Billion With Its Smart Bomb For Cancer? (abre em uma nova aba)

  15 de jul. de 2026

• Merck ADC, in China study, shows potential to replace chemo in lung cancer (abre em uma nova aba)

  15 de jul. de 2026

• Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Asthma (abre em uma nova aba)

  15 de jul. de 2026

• Kelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Asthma (abre em uma nova aba)

  15 de jul. de 2026